Menu
Development of anticancer drugs and gene therapies
Immugenia Inc. is developing the next generation of CAR-T therapy to treat and prevent relapses in hematological and solid cancers. This is achieved by engineering the patients’ hematopoietic stem cells and leveraging their synergistic activity. This provides patients with a one-and-done treatment to fight hard-to-treat cancers and prevent relapses.
Here are the companies that are at the heart of each of our decisions and that we are proud to support.
Together, let’s build the world of tomorrow.
